Research graph
References from Therapy-induced immunoediting and the evolution of cancer immune escape. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion
10.1126/science.1203486 · 2011 · External reference
Cancer immunoediting hypothesis: history, clinical implications and controversies
10.5114/ceji.2022.117376 · 2022 · External reference
The three Es of cancer immunoediting
10.1146/annurev.immunol.22.012703.104803 · 2004 · External reference
Cancer immunoediting and resistance to T cell-based immunotherapy
2019 · External reference
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape
10.1016/j.coi.2014.01.004 · 2014 · External reference
Cancer immunoediting in the era of immuno-oncology
10.1158/1078-0432.ccr-21-1804 · 2022 · External reference
Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis
10.3389/fimmu.2025.1655176 · 2025 · External reference
Immune checkpoint blockade in cancer therapy
10.1200/jco.2014.59.4358 · 2015 · External reference
Boosting cancer immunotherapy: drug delivery systems leveraging ferroptosis and immune checkpoint blockade
10.3389/fimmu.2025.1611299 · 2025 · External reference
Dying of stress: chemotherapy, radiotherapy, and small-molecule inhibitors in immunogenic cell death and immunogenic modulation
10.3390/cells11233826 · 2022 · External reference
Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment
10.3389/fimmu.2022.1074477 · 2022 · External reference
The evolving relationship of wound healing and tumor stroma
10.1172/jci.insight.99911 · 2018 · External reference
Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
10.1038/s41392-023-01383-x · 2023 · External reference
Tumor antigen escape from CAR T-cell therapy
10.1158/2159-8290.cd-18-0442 · 2018 · External reference
Sarcopenia associated with chemotherapy and targeted agents for cancer therapy
10.21037/apm.2018.08.02 · 2019 · External reference
Primary, adaptive, and acquired resistance to cancer immunotherapy
10.1016/j.cell.2017.01.017 · 2017 · External reference
Cancer immune evasion, immunoediting and intratumour heterogeneity
10.1038/s41577-024-01111-8 · 2025 · External reference
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
10.1016/j.ccell.2023.02.016 · 2023 · External reference
The cytokines in tumor microenvironment: from cancer initiation-elongation-progression to metastatic outgrowth
10.1016/j.critrevonc.2024.104311 · 2024 · External reference
Clonal heterogeneity and tumor evolution: past, present, and the future
10.1016/j.cell.2017.01.018 · 2017 · External reference
Clonal evolution in cancer
10.1038/nature10762 · 2012 · External reference
Cancer immunotherapy using checkpoint blockade
10.1126/science.aar4060 · 2018 · External reference
Mutations associated with acquired resistance to PD-1 blockade in melanoma
10.1056/nejmoa1604958 · 2016 · External reference
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations
10.1158/2159-8290.cd-16-1223 · 2017 · External reference
Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy
10.3389/fimmu.2024.1389173 · 2024 · External reference
Detection of immunogenic cell death and its relevance for cancer therapy
10.1038/s41419-020-03221-2 · 2020 · External reference
MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells
10.1158/2326-6066.cir-13-0181 · 2014 · External reference
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
10.1016/j.cell.2017.01.010 · 2016 · External reference
Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies
10.1016/j.biopha.2024.117252 · 2024 · External reference
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
10.1126/science.aaf1490 · 2016 · External reference
Allele-specific HLA loss and immune escape in lung cancer evolution
10.1158/1557-3265.aacriaslc18-ia23 · 2017 · External reference
Neoantigens in cancer immunoediting: from mechanisms to personalized vaccines in breast cancer
10.3389/fcell.2025.1733549 · 2026 · External reference
Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy
10.1158/2159-8290.cd-15-1020 · 2015 · External reference
Mechanisms of drug resistance in melanoma
10.1007/164_2017_17 · 2018 · External reference
Resisting T cell attack: tumor-cell-intrinsic defense and reparation mechanisms
10.1016/j.trecan.2022.12.003 · 2023 · External reference
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
10.1056/nejmoa1113205 · 2012 · External reference
Tracking the evolution of non-small-cell lung cancer
10.2217/lmt.15.11 · 2017 · External reference
Non-genetic mechanisms of therapeutic resistance in cancer
10.1038/s41568-020-00302-4 · 2020 · External reference
How tumor cell dedifferentiation drives immune evasion and resistance to immunotherapy
10.1158/0008-5472.can-20-1420 · 2020 · External reference
Epigenetic silencing of TAP1 in Aldefluor(+) breast cancer stem cells contributes to their enhanced immune evasion
10.1002/stem.2780 · 2018 · External reference
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
10.1016/j.cell.2010.02.027 · 2010 · External reference
Epithelial-mesenchymal plasticity in tumor immune evasion
10.1158/0008-5472.can-21-4370 · 2022 · External reference
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
10.1038/s41467-018-04313-6 · 2018 · External reference
Breast cancer stem cells secrete MIF to mediate tumor metabolic reprogramming that drives immune evasion
10.1158/0008-5472.can-23-2390 · 2024 · External reference
Principles and mechanisms of non-genetic resistance in cancer
10.1038/s41416-019-0648-6 · 2020 · External reference
TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure
10.1038/s41467-018-06654-8 · 2018 · External reference
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
10.1038/nature25501 · 2018 · External reference
Targeting the tumor vasculature to enhance T cell activity
10.1016/j.coi.2015.01.011 · 2015 · External reference
Lactylation in cancer progression and drug resistance
10.1016/j.drup.2025.101248 · 2025 · External reference
Targeting tumor-associated macrophages to synergize tumor immunotherapy
10.1038/s41392-021-00484-9 · 2021 · External reference
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
10.1038/s41577-020-00490-y · 2021 · External reference
A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging
10.1016/j.cell.2018.08.039 · 2018 · External reference
Single-cell landscape of intratumoral heterogeneity and tumor microenvironment remolding in pre-nodal metastases of breast cancer
10.1186/s12967-024-05625-6 · 2024 · External reference
Top 10 challenges in cancer immunotherapy
10.1016/j.immuni.2019.12.011 · 2020 · External reference
Understanding the tumor immune microenvironment (TIME) for effective therapy
10.1038/s41591-018-0014-x · 2018 · External reference
Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy
10.1158/1078-0432.ccr-20-3305 · 2021 · External reference
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
10.1038/s41467-021-25332-w · 2021 · External reference
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
10.1016/j.jhep.2021.11.030 · 2022 · External reference
Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: The phase II NeoCOAST platform trial
10.1158/2159-8290.cd-23-0436 · 2023 · External reference
Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: A randomized, open-label, phase 3 trial
10.1016/j.jtho.2023.08.018 · 2023 · External reference
ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer
10.1056/nejmoa2511885 · 2025 · External reference
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
10.1038/s41586-021-03642-9 · 2021 · External reference
Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma
10.1056/nejmoa2109970 · 2022 · External reference
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
10.1056/nejmoa1915745 · 2020 · External reference
COAST: An open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer
10.1200/jco.22.00227 · 2022 · External reference
Bempegaldesleukin plus nivolumab in untreated advanced melanoma: The open-label, phase III PIVOT IO 001 trial results
10.1200/jco.23.00172 · 2023 · External reference
Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma
10.1200/jco.22.00343 · 2023 · External reference
Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials
10.1002/ajh.26301 · 2021 · External reference
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell Malignancies: a phase 1 trial
10.1038/s41591-021-01436-0 · 2021 · External reference
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
10.1016/s0140-6736(24)00746-3 · 2024 · External reference
Glofitamab for relapsed or refractory diffuse large B-cell lymphoma
10.1056/nejmoa2206913 · 2022 · External reference
Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial
10.1200/jco.22.01725 · 2023 · External reference
Emerging insights into targeted therapy-tolerant persister cells in cancer
10.3390/cancers13112666 · 2021 · External reference
Immune cells in residual disease and recurrence
10.1016/j.trecan.2023.04.001 · 2023 · External reference
Mouse models in oncoimmunology
10.1038/nrc.2016.91 · 2016 · External reference
Humanized mouse models for immuno-oncology research
10.1038/s41571-022-00721-2 · 2023 · External reference
Patient-derived organoids for precision cancer immunotherapy
10.1158/0008-5472.can-20-4026 · 2021 · External reference
Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade
10.1158/2159-8290.cd-15-1545 · 2016 · External reference
Impact of circulating tumor DNA-based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors
10.1200/po.21.00181 · 2022 · External reference
Quantitative spatial profiling of TILs as the next step beyond PD-L1 testing for immune checkpoint blockade
10.1158/1078-0432.ccr-22-2277 · 2022 · External reference
